Physician profile
Samuel E Hall
NPI 1700858537
$6,195.06
in general payments reported to CMS, 2019-2025
25 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $590 · 2021: $4,156 · 2022: $99.74 · 2023: $306 · 2024: $73.28 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,967.45 | 2019-2024 | |
| Abbvie INC. | $402.52 | 2019-2023 | |
| Gynesonics, INC. | $381.55 | 2021-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Amag Pharmaceuticals, INC. | $201.77 | 2019 | |
| Astellas Pharma US INC | $186.00 | 2019-2025 | Veozah |
| Organon LLC | $127.22 | 2021-2025 | Nexplanon |
| Nevro Corp. | $120.08 | 2020 | |
| Therapeuticsmd, INC. | $119.92 | 2020-2021 | |
| Depuy Synthes Sales INC. | $117.80 | 2025 | Cerebase |
| Avion Pharmaceuticals | $96.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $93.30 | 2019-2021 | |
| Exeltis, USA INC. | $49.66 | 2024 | Slynd |
| Mylan Pharmaceuticals INC. | $45.19 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.80 | 2020-2021 | |
| Millicent US INC | $36.50 | 2021-2025 | Femlyv |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $33.71 | 2021 | |
| Duchesnay USA Incorporated | $28.91 | 2019 | |
| Abbott Laboratories | $21.03 | 2023 | Proclaim |
| Sanofi-Aventis U.S. LLC | $19.22 | 2019 | |
| Minerva Surgical, INC | $19.15 | 2019 | |
| Renovia INC | $19.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.98 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.94 | 2020 | |
| Allergan, INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.